Cargando…

Selective Serotonin Reuptake Inhibitors for the Treatment of Depression in Adults with Down Syndrome: A Preliminary Retrospective Chart Review Study

Background: Depression is a common psychiatric comorbidity in individuals with Down syndrome (DS), particularly adults, with an estimated lifetime prevalence of at least 10%. The current literature on the treatment of depression in adults with DS is limited to case series published more than two dec...

Descripción completa

Detalles Bibliográficos
Autores principales: Thom, Robyn P., Palumbo, Michelle L., Thompson, Claire, McDougle, Christopher J., Ravichandran, Caitlin T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469816/
https://www.ncbi.nlm.nih.gov/pubmed/34573236
http://dx.doi.org/10.3390/brainsci11091216
_version_ 1784574034879447040
author Thom, Robyn P.
Palumbo, Michelle L.
Thompson, Claire
McDougle, Christopher J.
Ravichandran, Caitlin T.
author_facet Thom, Robyn P.
Palumbo, Michelle L.
Thompson, Claire
McDougle, Christopher J.
Ravichandran, Caitlin T.
author_sort Thom, Robyn P.
collection PubMed
description Background: Depression is a common psychiatric comorbidity in individuals with Down syndrome (DS), particularly adults, with an estimated lifetime prevalence of at least 10%. The current literature on the treatment of depression in adults with DS is limited to case series published more than two decades ago, prior to the widespread use of modern antidepressant medications such as selective serotonin reuptake inhibitors (SSRIs). The purpose of this retrospective chart review study was to examine the effectiveness, tolerability, and safety of SSRIs for depression in adults with DS. Methods: Medical records of 11 adults with DS and depression were reviewed. Assignment of scores for severity (S) of symptoms of depression and improvement (I) of symptoms with treatment with an SSRI was made retrospectively using the Clinical Global Impression Scale (CGI). Demographic and clinical characteristics of the study population, SSRI name, dose, and duration of treatment; and adverse effects were also recorded. Results: All 11 patients (7 male, 4 female; mean age = 27.2 years, range 18–46 years) completed a 12-week treatment course with an SSRI. The median duration of time after initiation of the SSRI covered by record review was 2.1 years, with a range of 24 weeks to 6.7 years. Nine of the 11 patients (82%; 95% CI 52%, 95%) were judged responders to SSRIs based on a rating of “much improved” or “very much improved” on the CGI-I after 12 weeks of treatment (median time of follow-up was 14.4 weeks, with a range of 12.0–33.0 weeks). Adverse effects occurred in four patients (36%). The most common adverse effects were daytime sedation and anger. Conclusions: In this preliminary retrospective study, the majority of patients responded to a 12-week course of SSRI treatment and some tolerated long-term use. Controlled studies are needed to further assess the efficacy, tolerability, and safety of SSRIs for the treatment of depression in adults with DS.
format Online
Article
Text
id pubmed-8469816
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84698162021-09-27 Selective Serotonin Reuptake Inhibitors for the Treatment of Depression in Adults with Down Syndrome: A Preliminary Retrospective Chart Review Study Thom, Robyn P. Palumbo, Michelle L. Thompson, Claire McDougle, Christopher J. Ravichandran, Caitlin T. Brain Sci Article Background: Depression is a common psychiatric comorbidity in individuals with Down syndrome (DS), particularly adults, with an estimated lifetime prevalence of at least 10%. The current literature on the treatment of depression in adults with DS is limited to case series published more than two decades ago, prior to the widespread use of modern antidepressant medications such as selective serotonin reuptake inhibitors (SSRIs). The purpose of this retrospective chart review study was to examine the effectiveness, tolerability, and safety of SSRIs for depression in adults with DS. Methods: Medical records of 11 adults with DS and depression were reviewed. Assignment of scores for severity (S) of symptoms of depression and improvement (I) of symptoms with treatment with an SSRI was made retrospectively using the Clinical Global Impression Scale (CGI). Demographic and clinical characteristics of the study population, SSRI name, dose, and duration of treatment; and adverse effects were also recorded. Results: All 11 patients (7 male, 4 female; mean age = 27.2 years, range 18–46 years) completed a 12-week treatment course with an SSRI. The median duration of time after initiation of the SSRI covered by record review was 2.1 years, with a range of 24 weeks to 6.7 years. Nine of the 11 patients (82%; 95% CI 52%, 95%) were judged responders to SSRIs based on a rating of “much improved” or “very much improved” on the CGI-I after 12 weeks of treatment (median time of follow-up was 14.4 weeks, with a range of 12.0–33.0 weeks). Adverse effects occurred in four patients (36%). The most common adverse effects were daytime sedation and anger. Conclusions: In this preliminary retrospective study, the majority of patients responded to a 12-week course of SSRI treatment and some tolerated long-term use. Controlled studies are needed to further assess the efficacy, tolerability, and safety of SSRIs for the treatment of depression in adults with DS. MDPI 2021-09-15 /pmc/articles/PMC8469816/ /pubmed/34573236 http://dx.doi.org/10.3390/brainsci11091216 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Thom, Robyn P.
Palumbo, Michelle L.
Thompson, Claire
McDougle, Christopher J.
Ravichandran, Caitlin T.
Selective Serotonin Reuptake Inhibitors for the Treatment of Depression in Adults with Down Syndrome: A Preliminary Retrospective Chart Review Study
title Selective Serotonin Reuptake Inhibitors for the Treatment of Depression in Adults with Down Syndrome: A Preliminary Retrospective Chart Review Study
title_full Selective Serotonin Reuptake Inhibitors for the Treatment of Depression in Adults with Down Syndrome: A Preliminary Retrospective Chart Review Study
title_fullStr Selective Serotonin Reuptake Inhibitors for the Treatment of Depression in Adults with Down Syndrome: A Preliminary Retrospective Chart Review Study
title_full_unstemmed Selective Serotonin Reuptake Inhibitors for the Treatment of Depression in Adults with Down Syndrome: A Preliminary Retrospective Chart Review Study
title_short Selective Serotonin Reuptake Inhibitors for the Treatment of Depression in Adults with Down Syndrome: A Preliminary Retrospective Chart Review Study
title_sort selective serotonin reuptake inhibitors for the treatment of depression in adults with down syndrome: a preliminary retrospective chart review study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469816/
https://www.ncbi.nlm.nih.gov/pubmed/34573236
http://dx.doi.org/10.3390/brainsci11091216
work_keys_str_mv AT thomrobynp selectiveserotoninreuptakeinhibitorsforthetreatmentofdepressioninadultswithdownsyndromeapreliminaryretrospectivechartreviewstudy
AT palumbomichellel selectiveserotoninreuptakeinhibitorsforthetreatmentofdepressioninadultswithdownsyndromeapreliminaryretrospectivechartreviewstudy
AT thompsonclaire selectiveserotoninreuptakeinhibitorsforthetreatmentofdepressioninadultswithdownsyndromeapreliminaryretrospectivechartreviewstudy
AT mcdouglechristopherj selectiveserotoninreuptakeinhibitorsforthetreatmentofdepressioninadultswithdownsyndromeapreliminaryretrospectivechartreviewstudy
AT ravichandrancaitlint selectiveserotoninreuptakeinhibitorsforthetreatmentofdepressioninadultswithdownsyndromeapreliminaryretrospectivechartreviewstudy